Abstract:
Paraoxonase-1 (PON-1) is an enzyme with a glycoprotein structure that depends on
calcium and it has cardio protective effects that protect low-density lipoprotein
(LDL) and high-density lipoprotein (HDL) from oxidation and therefore retards
atherosclerosis. As patients with chronic kidney disease (CKD) are at high risk of
atherosclerotic, in this study, we aimed to investigate serum PON-1 activity and
concentration levels among patients with 4th stage of CKD compared with the
healthy control subjects, to find out the possibility of taking the PON-1 as a
predictor marker of atherosclerosis in 4th stage of CKD patients.
Materials and Methods: This study included 30 patients with confirmed diagnosis
of 4th stage of CKD, and 30 healthy persons. Serum blood urea, creatinine, uric
acid, Albumin, total cholesterol, HDL, LDL and serum triglycerides were measured.
Serum level of PON-1 concentration was measured using ELISA technique, while
Serum level of PON-1 activity was detected using a colorimetric method.
Results: Our study showed significant increase (p<0.001) in the levels of
Cholesterol, Triglyceride, LDL and VLDL in patients with 4th stage of CKD as
compared to control group. Also, we found significant decreased levels of serum
HDL and PON-1 in 4th stage of CKD as compared to control group (p<0.001).
Conclusion: The diminution in the serum paraoxonase-1 activity and concentration
may contribute to the accelerated development of atherosclerosis in patients with
stage 4 of chronic kidney disease
